Feb 2014

Meptin Swinghaler, Easy-to-inhale Bronchodilator for COPD and Asthma Patients, Approved in Japan


  • Meptin is a short-acting beta agonist with rapid onset of pharmacological effect, widely used for asthma attacks. Newly approved Meptin Swinghaler is a smaller device than the inhaler currently marketed by Otsuka, making inhalation easier.
  • In Japan, there are an estimated 1.05 million asthma patients, including a significant elderly patient population. By 2011, the number of deaths related to asthma had fallen to approximately 2,000. Short-acting beta agonists in dry-powder-inhaler form, in an easy-to-use device for both pediatric and elderly patients, are crucial features of bronchodilators in order to save patients who experience severe asthma attacks.
  • Meptin was created by Otsuka and launched in 1980, indicated for bronchial asthma, chronic bronchitis, and pulmonary emphysema. It has been developed into seven dosage forms adapted to various patients needs, and is marketed in twelve countries and regions. Newly approved Meptin Swinghaler is the twelfth product under the Meptin brand, and is an improved form of the dry powder inhaler launched in 2005.

Tokyo, Japan, February 17, 2013 - Otsuka Pharmaceutical Co., Ltd. received regulatory approval on February 14 in Japan for Meptin Swinghaler (procaterol hydrochloride hydrate) 10μg, 100 puffs.

Information in this news release was current as of the original release date.


Otsuka Pharmaceutical Co., Ltd. (OPC) is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health. 

In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and also has research programs for several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. 

Otsuka Canada Pharmaceutical Inc. (OCPI) is an innovative, fast-growing health care company that commercializes Otsuka medicines in Canada. OCPI aims to improve the quality of life and health of patients through its commitments to neuroscience, cardiovascular health, oncology and nephrology. OCPI was established in 2010, with headquarters in Saint-Laurent, Quebec.


OCPI is part of Otsuka Pharmaceutical Co., Ltd., a wholly owned subsidiary of Otsuka Holdings Co., Ltd., based in Tokyo, Japan. The Otsuka group of companies employed 45,000 people worldwide and had consolidated sales of approximately CAD 14.5 billion (USD 11 billion) in 2016.

About Us
Contact Us

1 888 997-9017
514 332-3001

2250 Alfred-Nobel Boulevard,
St-Laurent, Quebec,
Suite 301
H4S 2C9